日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.

对致癌MET融合基因的泛癌分析揭示了对MET靶向治疗具有不同敏感性的不同致病基因组亚群

Febres-Aldana Christopher A, Vojnic Morana, Odintsov Igor, Zhang Tom, Cheng Ryan, Beach Catherine Z, Lu Daniel, Mattar Marissa S, Gazzo Andrea M, Gili Leo, Harshan Manju, Ameri Ali, Machnicki Stephen, Xiao Xiuying, Lockwood William W, Zhou Xiao-Yan, Yao Qianlan, Drilon Alexander, Rekhtman Natasha, Shah Nameeta, Li Anqi, Liu Zebing, Yang Soo-Ryum, Davare Monika A, Ladanyi Marc, Somwar Romel

Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study

瑞博西尼联合多柔比星序贯治疗蒽环类药物初治的晚期软组织肉瘤:一项剂量探索性 Ib 期研究的结果

Davis, Lara E; Zhu, Limin; Latour, Emile; McMahon, Nathan; Nishikawa, Go; Choo, Florence; Nusser, Kevin D; Pittsenbarger, Janét; Burch, Reid; Park, Byung; Mills, Gordon B; Davis, Jessica L; Davare, Monika; Ryan, Christopher W

Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma

复发性胶质母细胞瘤中新型MDM2::PDGFRA融合的临床和临床前研究进展

Beach, Catherine Z; Febres-Aldana, Christopher A; Marti, Juan Luis Gomez; Asiry, Saeed; Wong, Tamika; Boockvar, John A; D'Amico, Randy S; Somwar, Romel; Davare, Monika A; Vojnic, Morana

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

作者更正:TKI类型转换可克服ROS1融合阳性癌症中的ROS1 L2086F突变

Thawani, Rajat; Repetto, Matteo; Keddy, Clare; Nicholson, Katelyn; Jones, Kristen; Nusser, Kevin; Beach, Catherine Z; Harada, Guilherme; Drilon, Alexander; Davare, Monika A

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

TKI 类型转换可克服 ROS1 融合阳性癌症中的 ROS1 L2086F 突变

Thawani Rajat, Repetto Matteo, Keddy Clare, Nicholson Katelyn, Jones Kristen, Nusser Kevin, Beach Catherine Z, Harada Guilherme, Drilon Alexander, Davare Monika A

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain

通过胞外结构域的丧失对 ROS1 催化激活机制的新见解

Kristen Jones #, Clare Keddy #, Chelsea Jenkins, Katelyn Nicholson, Ujwal Shinde, Monika A Davare

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

作者更正:Vepafestinib 是一种药理学上先进的 RET 选择性抑制剂,具有高中枢神经系统穿透性和对 RET 溶剂前沿突变的抑制活性。

Miyazaki, Isao; Odintsov, Igor; Ishida, Keiji; Lui, Allan J W; Kato, Masanori; Suzuki, Tatsuya; Zhang, Tom; Wakayama, Kentaro; Kurth, Renate I; Cheng, Ryan; Fujita, Hidenori; Delasos, Lukas; Vojnic, Morana; Khodos, Inna; Yamada, Yukari; Ishizawa, Kota; Mattar, Marissa S; Funabashi, Kaoru; Chang, Qing; Ohkubo, Shuichi; Yano, Wakako; Terada, Ryuichiro; Giuliano, Claudio; Lu, Yue Christine; Bonifacio, Annalisa; Kunte, Siddharth; Davare, Monika A; Cheng, Emily H; de Stanchina, Elisa; Lovati, Emanuela; Iwasawa, Yoshikazu; Ladanyi, Marc; Somwar, Romel

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

发现对酪氨酸激酶抑制剂敏感的致癌 ROS1 错义突变

Sudarshan R Iyer #, Kevin Nusser #, Kristen Jones #, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion

II型RAF抑制剂托沃拉非尼在携带新型SNX8-BRAF基因融合的复发性梭形细胞肉瘤患儿中的活性

Offer, Katharine; McGuire, Michael T; Song, Kunchang; Goldfischer, Michael J; Davare, Monika A; Corless, Christopher L; Beadling, Carol; Neff, Tanaya; Cox, Michael C; Govinda Raju, Sandya; Blackman, Samuel C

Visual information following object grasp supports digit position variability and swift anticipatory force control

抓握物体后的视觉信息有助于手指位置的灵活变化和快速的预判性力量控制。

Bland, Joshua T; Davare, Marco; Marneweck, Michelle